Profiles of outer membrane proteins and lipopolysaccharide of Pseudomonas aeruginosa grown in the presence of sub-MICs of macrolide antibiotics and their relation to enhanced serum sensitivity.
We have previously reported that erythromycin at sub-inhibitory concentrations enhanced the serum sensitivity of some Pseudomonas aeruginosa strains. To explore the mechanism of this effect, we have now examined the influence of macrolide antibiotics on outer membrane proteins and lipopolysaccharide (LPS) of P. aeruginosa. The strains S-6 and PAO-1 of P. aeruginosa were used as susceptible and resistant strains respectively to assess enhancement of serum sensitivity by erythromycin. The strain S-6 became more serum-sensitive when grown on agar with sub-MICs of erythromycin or azithromycin, but not of josamycin, whereas no change was observed in the serum sensitivity of the strain PAO-1 after growth with any of these antibiotics. The analysis of outer membrane proteins showed that erythromycin treatment resulted in a reduction in the amount of the 38 kDa protein (OprF) and in a prominent increase of 41 kDa protein band in the strain S-6, but not in the strain PAO-1. By an immunoblotting assay, this 41 kDa protein was shown to be highly reactive to the immune serum against untreated P. aeruginosa. LPS of the strain S-6 were examined by SDS acrylamide gel electrophoresis. The treatment with erythromycin or azithromycin, but not with josamycin, reduced the amounts of LPS species with lower molecular weights although the levels of LPS species with high molecular weights were similar to those of untreated bacteria. These results suggest that the enhanced serum sensitivity of P. aeruginosa by erythromycin is associated with changes in bacterial surface components, such as outer membrane proteins and LPS.
Tateda
K
K
Department of Microbiology, Toho University School of Medicine, Japan.
Ishii
Y
Y
Hirakata
Y
Y
Matsumoto
T
T
Ohno
A
A
Yamaguchi
K
K
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017963:Azithromycin / Q000494:pharmacology; D001425:Bacterial Outer Membrane Proteins / Q000032:analysis / Q000187:drug effects*; D001769:Blood / Q000382:microbiology; D004917:Erythromycin / Q000494:pharmacology; D006801:Humans; D015151:Immunoblotting; D015570:Josamycin / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000032:analysis*; D008826:Microbial Sensitivity Tests; D011550:Pseudomonas aeruginosa / Q000737:chemistry / Q000187:drug effects*; D013400:Sugar Acids / Q000032:analysis
D000900:Anti-Bacterial Agents; D001425:Bacterial Outer Membrane Proteins; D008070:Lipopolysaccharides; D013400:Sugar Acids; C002532:2-keto-3-deoxyoctonate; D004917:Erythromycin; D017963:Azithromycin; D015570:Josamycin